Trinchieri V, Ferone U, Monacelli M, Isceri L, Proietti F, Sorice F
Dipartimento di Mallattie Infettive e Tropicali, Università degli Studi La Sapienza, Roma.
Riv Eur Sci Med Farmacol. 1996 Mar-Apr;18(2):49-51.
In this study the authors report the case of HIV patients with visceral leishmaniasis. He presented a pancreatitis with evident clinical signs and high increase of amilasis (9876 U/L) the twelfth day of treatment with meglumine antimoniate. The interruption of therapy was followed by a rapid disappearance of signs and symptoms and a normalization of amilasis. In accordance with the most recent studies, it is expedient, for every patients treated with antimonial drugs, to undergo an accurate amilasis monitoring.
